Skriv ut
Kategori: Nyheter
Meeting venue
Aula Medica - Karolinska Institute Nobels Väg 6 - 171 65 Stockholm
 
Registration hours:
Friday, 1 December: 13:30 - 17:30
Saturday, 2 December: 07:30 - 17:30
Sunday, 3 December: 07:30 - 13:00
 
Official language
English. Simultaneous translation will not be provided.
 
Registrations
No registration fee is required to attend the Conference.
 
Please return the registration form to:
AVEC S.r.l. - Incentive Paintings Via Lavoratori Autobianchi, 1
c/o Polo Tecnologico Brianza - Edificio 9 - Ufficio 14
I-20832 Desio (MB, Italy)
Phone: +39 0362 581579 – Fax: +39 0362 1860074
E-mail: Den här e-postadressen skyddas mot spambots. Du måste tillåta JavaScript för att se den.
 
Congress website
www.cardiometabolic-risk-stockholm2017.com
 
I wish you a warm welcome to the symposium ”Cardiometabolic Risk and Vascular Disease: from Mechanisms to Treatment” here in Stockholm from 1-3 December 2017.
 
This three-day programme offers a comprehen-sive update of cardiometabolic risk presented by a distinguished interna-tional teaching faculty.
 
The educational objectives are to review and disseminate the latest knowledge about advances in the pathophysiology, diagnosis and treat-ment of cardiometabolic risk and to discuss its impact in clinical practice.
 
The scientific programme covers a broad spectrum of topics including the relationship between immunity and metabolism as well as inflammation and atherosclerosis; preventive strategies; evidence-based management of obesity and insulin resistance; atherothrombosis and strategies beyond glycemic control; diabetes, acute coronary syndromes and heart failure. State of the art lectures alternate with interactive sessions.
Our Symposium is designed to promote a working and learning environ-ment across specialty borders.
I am looking forward to meeting you in Stockholm.
 
Francesco Cosentino, MD, PhD, FESC
 
Day 1
Friday / 1 December / Afternoon
14:30 - 15:15 Welcome address
15:15 - 17:00 Session I
Novel Mechanisms of Disease
Chair: L. Badimon (Barcelona), L. Ryden (Stockholm)
15:15 - 15:35 The microbiom: a new theory of atherosclerosis
T.F. Luscher (Zurich)
15:35 - 15:55 Epigenetics and cardiometabolic risk
Cosentino (Stockholm)
15:55 - 16:15 The relationship between immunity
and metabolism
T.J. Guzik (Glasgow)
16:15 - 16:35 Metabolism, adipose tissue and CVD
Minamino (Niigata)
16.35 - 17:00 Discussion
17:00 - 17:30 Lecture: Redox signalling in the healthy
and diseased myocardium
Chair: M. Pfeffer (Boston)
Speaker: B. Casadei (Oxford)
 
Day 2
Saturday / 2 December / Morning
08:30 - 10:15 Session II
Atherosclerosis
Chair: B. Casadei (Oxford)
Pernow (Stockholm)
08:30 - 08:50 Novel aspects of platelet biology
Badimon (Barcelona)
08:50 - 09:10 Understanding the vulnerable plaque
Crea (Rome)
09:10 - 09:30 Is HDL atheroprotective:
current controversies
Landmesser (Berlin)
09:30 - 09:50 RAGE and atherosclerosis
A.M. Schmidt (New York)
09.50-10:15 Discussion
10:15-10:45 Coffee break
10:45 - 12:30 Session III
CV Risk Factors and Preventive Strategies
Chair: M.L. Hellenius (Stockholm)
T.F. Luscher (Zurich)
10:45 - 11:05 Obesity in CVD: friend or foe?
J.-P. Despres (Quebec)
11:05 - 11:25 Current challenges and future perspectives
in hypertension
Volpe (Rome)
11:25 - 11:45 Treatment of dyslipidemias: what is new?
Graham (Dublin)
11:45 - 12:05 Prevention of CVD: quo vadis?
D.E. Grobbee (Utrecht)
12:05 - 12.30 Discussion
12:30 - 13.30 Lunch
13:30 - 15:15 Session IV
Improving Evidence-Based Management of Cardiometabolic Risk Chair: A. Hamsten (Stockholm)
Volpe (Rome)
13:30 - 13:50 Lifestyle and cardiometabolic risk
M.L. Hellenius (Stockholm)
13:50 - 14:10 Blood pressure variability and CV risk
Parati (Milan)
14:10 - 14:30 Getting patients to target
K.K. Ray (London)
14:30 - 14:50 Residual CVD risk: where are we?
Ambrosio (Perugia)
14:50 - 15:15 Discussion
15:15 - 15:45 Coffee break
15:45 - 17:30 Session V
Preventing Atherothrombotic CVD
Strategies beyond Glycemic Control
Chair: D.J. Angiolillo (Jacksonville)
Braunschweig (Stockholm)
15:45 - 16:05 Update on CVOTs in diabetes
Ryden (Stockholm)
16:05- 16:25 Can real-world data in diabetes add to clinical practice decisions? S. Gudbjörnsdottir (Göteborg)
16:25 - 16:45 Antiplatelet therapy
Patrono (Rome)
16:45 - 17:05 Tailoring antithrombotic therapy to patient,
procedure, stent S. Windecker (Bern)
17:05 - 17:30 Discussion
 
Day 3
Sunday / 3 December / Morning
08:30 - 10:20 Session VI
Diabetes and the Heart
Chair: F. Crea (Rome)
Seferovic (Belgrade)
08:30 - 08:50 Diabetic cardiomyopathy: myth or reality?
Pinto (Lisbon)
08:50 - 09:10 Imaging fibrosis in the diabetic heart
J.J. Bax (Leiden)
09:10- 09:30 SGLT2 inhibition, a paradigm shift
Ruschitzka (Zurich)
09:30 - 09:50 Heart failure patients with comorbidities:
diabetes and renal dysfunction G. Filippatos (Athens)
09.50 - 10:20 Discussion
10:20 - 10:50 Coffee break
10:50 - 11:20 Nobel Lecture
Chair: J. Bax (Leiden)
Speaker: L. Ignarro (Los Angeles)
11:20 - 13:00 Session VII
Diabetes and Acute Coronary Syndromes
Chair: C. Linde (Stockholm)
Milicic (Zagreb)
11:20 - 11:40 Blood glucose lowering:
old problems, new promises M. Pfeffer (Boston)
11:40 - 12:00 Decision-making in the cath lab
Indolfi (Catanzaro)
12:00 - 12:20 DAPT: real-world clinical practice
D.J. Angiolillo (Jacksonville)
12:20 - 12:40 Management of ventricular arrhythmias
Hindricks (Leipzig)
12:40 - 13:00 Discussion
13:00 - 13:15 Closing remarks
13:15 - 14:15 Lunch
 
Nyhetsinfo
www red DiabetologNytt
 
 
 
Träffar: 2369